Quarter 2 in brief
The company’s partners NeoTX presented new preclinical data for ANYARA at the conference of the AACR in Chicago
During the april share issue provided the company 47,1 million
Events after the end of the period
The company announces that the phase 2 study in LEGATO-HD, which evaluates the efficacy and safety of laquinimod in Huntington’s disease (HD), not achieved its primary objective to slow down the progression of the disease. However, achieved the secondary objective, the reduction of hjärnatrofi. Laquinimod demonstrated excellent safety in the study
The company launches a scientific work with The Wistar Institute, Philadelphia in the united states, around the tasquinimod in order to support future clinical development in multiple myeloma
For further information, please contact:
Helén and Held, PRESIDENT
Tel 046-19 21 56
Hans Kolam, CFO
Tel 046-19 20 44
Active Biotech AB
Box 724, 220 07 Lund, Sweden
Tel 046-19 20 00
The report is also available on the www.activebiotech.com.
Active Biotech AB Interim report January — June 2018
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire